Wright Investors Service Inc. Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Wright Investors Service Inc. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,665 shares of the biopharmaceutical company's stock after buying an additional 2,484 shares during the quarter. Gilead Sciences accounts for approximately 1.9% of Wright Investors Service Inc.'s holdings, making the stock its 14th biggest holding. Wright Investors Service Inc.'s holdings in Gilead Sciences were worth $5,677,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Redwood Financial Network Corp boosted its position in shares of Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock worth $234,000 after acquiring an additional 98 shares in the last quarter. Nicolet Advisory Services LLC grew its position in shares of Gilead Sciences by 2.9% during the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after acquiring an additional 100 shares during the last quarter. CFO4Life Group LLC grew its position in shares of Gilead Sciences by 2.7% during the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock worth $394,000 after acquiring an additional 112 shares during the last quarter. Howe & Rusling Inc. grew its position in shares of Gilead Sciences by 2.5% during the fourth quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company's stock worth $435,000 after acquiring an additional 115 shares during the last quarter. Finally, Atalanta Sosnoff Capital LLC grew its position in shares of Gilead Sciences by 4.7% during the fourth quarter. Atalanta Sosnoff Capital LLC now owns 2,648 shares of the biopharmaceutical company's stock worth $245,000 after acquiring an additional 119 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on GILD shares. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research report on Thursday, February 13th. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Finally, Bank of America lifted their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 17,929 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the transaction, the chief financial officer now owns 169,061 shares of the company's stock, valued at $19,977,938.37. The trade was a 9.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,929 shares of company stock worth $6,748,980. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Up 1.8%

NASDAQ:GILD traded up $1.95 on Thursday, hitting $110.97. 4,627,772 shares of the company's stock traded hands, compared to its average volume of 7,723,252. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a 50-day moving average price of $105.40 and a 200-day moving average price of $101.15. The company has a market cap of $138.04 billion, a PE ratio of 299.92, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 1 year low of $62.69 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company's revenue was down .3% compared to the same quarter last year. During the same quarter last year, the business earned ($1.32) earnings per share. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.85%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.